Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

(2012) Paul J. Martin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival

(2012) Brian G. Engelhardt et al.   EXPERIMENTAL HEMATOLOGY

Novel treatment concepts for graft-versus-host disease

(2011) D. Wolf et al.   BLOOD

Prognostic value of response after upfront therapy for acute GVHD

(2011) R M Saliba et al.   BONE MARROW TRANSPLANTATION

Graft-versus-Host Disease Treatment: Predictors of Survival

(2010) John E. Levine et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The best endpoint for acute GVHD treatment trials

(2010) M. L. MacMillan et al.   BLOOD

Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement

(2009) Paul J. Martin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Study design and endpoints in graft-versus-host disease

(2008) Paul J. Martin   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY